The in vitro anti-atherosclerotic activity of compound IMB-1680 / 药学学报
Acta Pharmaceutica Sinica
;
(12): 602-607, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-245040
ABSTRACT
In the previous study, a high-throughput screening method was established to find the antagonists of CD36. In the present study, a new compound named IMB-1680 was found using this method. The anti-atherosclerotic activities of IMB-1680 were then evaluated. Dose-dependent activities of IMB-1680 were detected by using Sf9 [hCD36] and CHO [hCD36] models. Fluorescence microscopic photography and flow cytometry were used to analyze uptake of mLDL. Foam cell test with RAW264.7 macrophages was used to examine lipid accumulation. The results showed that IMB-1680 inhibited CD36 activity with IC50 of 2.80 and 8.79 micromol x L(-1) in Sf9[hCD36] and CHO [hCD36] cells, respectively. Fluorescence microscopic photography and flow cytometry revealed that IMB-1680 could significantly reduce DiI-AcLDL uptake. Meanwhile, IMB-1680 also could reduce lipids accumulation in RAW264.7 macrophages. In all, the data indicated that IMB-1680 might be a potent effective anti-atherosclerotic leading compound.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasmids
/
Transfection
/
Molecular Structure
/
Cells, Cultured
/
Cricetulus
/
CHO Cells
/
Spodoptera
/
CD36 Antigens
/
Cell Biology
/
Dose-Response Relationship, Drug
Limits:
Animals
/
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS